Skip to main content

Table 2 Active or completed phase III clinical trials of Akt inhibitors

From: Targeting Akt in cancer for precision therapy

Trial ID Official title Akt inhibitor Combination Cancer type Phase Molecular markers Estimated enrollment
NCT03997123 CAPItello-290 Capivasertib Paclitaxel TNBC III ER/PR/HER2 924
NCT04862683 CAPItello-292 Capivasertib Fulvestrant
Palbociclib
Locally advanced or metastatic breast cancer III HR+/HER2 628
NCT04305496 CAPItello-291 Capivasertib Fulvestrant Locally advanced or metastatic breast cancer III HR+/HER2 834
NCT04493853 CAPItello-281 Capivasertib Abiraterone Hormone sensitive prostate cancer III AR 1000
NCT03072238a IPATential150 Ipatasertib Abiraterone
Prednisolone
Metastatic prostate cancer III PTEN 1101
NCT03337724 IPATunity130 Ipatasertib Paclitaxel Locally advanced or metastatic breast cancer III PIK3CA/AKT1/PTEN
ER/PR/HER2HR+/HER2
580
NCT04060862 IPATunity150 Ipatasertib Fulvestrant
Palbociclib
Locally advanced or metastatic breast cancer III HR+’HER2 N.A
NCT04650581 FINER Ipatasertib Fulvestrant Advanced breast cancer following progression on first-line CDK4/6 inhibitor and aromatase inhibitor III ER+/HER2 250
NCT04177108 N.A Ipatasertib Atezolizumab
Paclitaxel
Locally advanced or metastatic breast cancer III ER/PR/HER2 242b
  1. N.A. not available
  2. aThis trial has been finished.
  3. bThe actual enrollment number as updated in January 2021